FDA Approved: TRESIBA — Supplemental Application (Novo Nordisk)

View source ↗

Summary

The FDA approved a supplemental application for TRESIBA (insulin degludec) filed by Novo Nordisk.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus
• Type 2 Diabetes Mellitus

Drugs mentioned

• Tresiba (insulin degludec)

Snippet

SUPPL AP for TRESIBA (INSULIN DEGLUDEC)